Kane Biotech Inc. (CVE:KNE – Get Free Report)’s share price reached a new 52-week low on Tuesday . The stock traded as low as C$0.02 and last traded at C$0.02, with a volume of 45000 shares traded. The stock had previously closed at C$0.03.
Kane Biotech Stock Performance
The firm has a market capitalization of C$3.08 million, a P/E ratio of -1.50 and a beta of 1.05. The business’s 50 day simple moving average is C$0.03 and its two-hundred day simple moving average is C$0.03. The company has a current ratio of 0.45, a quick ratio of 0.39 and a debt-to-equity ratio of -135.17.
Kane Biotech Company Profile
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.
See Also
- Five stocks we like better than Kane Biotech
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
